Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
https://kalkinemedia.com/resources/assets/public/img/flags/au.png AUS
https://kalkinemedia.com/resources/assets/public/img/flags/nz.png NZ
https://kalkinemedia.com/resources/assets/public/img/flags/uk.png UK
https://kalkinemedia.com/resources/assets/public/img/flags/ca.png CA
https://kalkinemedia.com/resources/assets/public/img/flags/us.png USA
https://kalkinemedia.com/resources/assets/public/img/flags/fr.png FRA
https://kalkinemedia.com/resources/assets/public/img/flags/de.png GER
https://kalkinemedia.com/resources/assets/public/img/flags/es.png ESP
https://kalkinemedia.com/resources/assets/public/img/flags/it.png ITA
https://kalkinemedia.com/resources/assets/public/img/flags/nl.png NLD
https://kalkinemedia.com/resources/assets/public/img/flags/pt.png PRT
https://kalkinemedia.com/resources/assets/public/img/flags/se.png SWE
https://kalkinemedia.com/resources/assets/public/img/flags/gr.png GRC
https://kalkinemedia.com/resources/assets/public/img/flags/in.png IND
https://kalkinemedia.com/resources/assets/public/img/flags/pl.png POL
https://kalkinemedia.com/resources/assets/public/img/flags/br.png BRA
https://kalkinemedia.com/resources/assets/public/img/flags/za.png ZAF
https://kalkinemedia.com/resources/assets/public/img/flags/ru.png RUS
https://kalkinemedia.com/resources/assets/public/img/flags/cn.png CHN
https://kalkinemedia.com/resources/assets/public/img/flags/ae.png UAE
Kalkine Media ASX Share Market News & Research

Earnings Per Share Trends in Actinium Pharmaceuticals (NYSE:ATNM)

May 19, 2025 09:14 AM WEST | By Team Kalkine Media
Earnings Per Share Trends in Actinium Pharmaceuticals (NYSE:ATNM)
Image source: shutterstock

Recent News

thumbnail

Moinho do Zorrão reopens as a charming rural accommodation in the hear...

thumbnail

TravelingWiki Promotes Autism with World Renowned S.L. Benfica & Head...

thumbnail

AVer Europe y Charmex anuncian una alianza estratégica de distribución

thumbnail

North to Shore: New Jersey’s Premier Cultural Festival Welcomes Portug...

Highlights

  • Dimensional Fund Advisors notably decreased its shares in Actinium Pharmaceuticals.
  • Renaissance Technologies and JPMorgan Chase significantly increased their stakes.
  • The stock’s average rating remains at with fluctuating market performance.

Actinium Pharmaceuticals (NYSE:ATNM) operates within the healthcare sector and is listed on Earnings Per Share. The company is recognized for its focus on developing targeted radiotherapy treatments, with a flagship product aimed at addressing difficult blood cancers. Recent activity in major fund holdings reflects shifting positions among prominent financial entities.

Institutional Share Changes

During the last quarter, Dimensional Fund Advisors reduced its stake in Actinium Pharmaceuticals by a substantial margin, decreasing the total shares it controls. Meanwhile, Renaissance Technologies increased its ownership considerably, adding a significant number of shares. JPMorgan Chase showed the most notable increase, expanding its position by a very large percentage, indicating a marked interest from this financial entity.

Analyst Ratings and Market Performance

Actinium Pharmaceuticals carries an average rating categorized as from market watchers, with some entities offering differing views on the stock's outlook. The stock price has experienced wide variation within the past year, moving between a low point and a peak that reflects market volatility. The company’s market value remains relatively modest compared to larger peers in the sector. It also shows a negative price-to-earnings ratio, a common feature among firms in developmental or specialized pharmaceutical areas.

Company Focus and Sector Context

The company’s primary focus is on radiotherapy products designed to improve patient outcomes in hematologic cancers, (NYSE:ATNM) specifically relapsed and refractory acute myeloid leukemia. Actinium Pharmaceuticals’ ongoing development programs are pivotal in its profile. Its position on the Best Dividend Stocks its status as a mid-sized firm with a specialized pipeline in the biopharmaceutical arena.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles